<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01453192</url>
  </required_header>
  <id_info>
    <org_study_id>2011-001004-35</org_study_id>
    <secondary_id>ANRS 153 TREVE</secondary_id>
    <nct_id>NCT01453192</nct_id>
  </id_info>
  <brief_title>Renal Transplantation and Raltegravir in HIV-Infected Patients</brief_title>
  <acronym>ANRS153TREVE</acronym>
  <official_title>National, Multicenter, Phase III Prospective Trial About Clinical and Immunological Follow-up After Renal Transplantation in HIV-1 Infected Patients With End Stage Chronic Renal Insufficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the incidence of acute renal graft rejection 6 months
      after transplantation in HIV-infected patients under three antiretroviral drugs regimen
      including Raltegravir.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Antiretroviral treatment of HIV-1 Infection might interact with immunosuppressive treatments
      which increase rejection of renal graft incidence.

      In addition HIV infection may be modified together with cardiovascular risk. Patients
      participating to this study will receive after transplantation antiretroviral regimen
      including Raltegravir.

      Raltegravir treatment does not interact with immunosuppressive drugs and thus seems to be the
      treatment of choice to be associated with immunosuppressive drugs.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of acute clinical renal graft rejection</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence of acute clinical renal graft rejection defined by 20% increase of serum creatinine, associated to histological features (Banff classification) 6 months after renal transplantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute clinical and subclinical renal graft rejection</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of acute clinical and subclinical renal graft rejection up to 1 year after renal transplantation defined only by renal histology (without creatinine modification). Histology is performed on routine renal graft biopsy 3 months and 1 year after transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One year graft survival</measure>
    <time_frame>1 year</time_frame>
    <description>One year graft survival, compared to non HIV-infected transplanted patients, using data provided by French Biomedicines Agency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' survival</measure>
    <time_frame>1 year</time_frame>
    <description>Patients survival, compared to:
- chronic dialysis HIV patients still listed on the transplantation waiting list - transplanted non-HIV patients using data provide by French Biomedicine Agency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phenotyping of lymphocytic infiltrates in case of acute rejection</measure>
    <time_frame>1 year</time_frame>
    <description>The aim of the immunological phenotyping is to analyse the expression of activation markers between different TCD4 and TCD8 sub-population, this phenotyping will be compared to those observed in acute cell-mediated rejection occurring in the historical cohort of Non-HIV patients. In addition, the rate and expression of Treg population will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AIDS defined diseases and severe morbidity diseases after renal transplantation</measure>
    <time_frame>1 year</time_frame>
    <description>Severe morbidity diseases include: pathological infections, malignancies, metabolic and cardiovascular diseases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological and virologic status after renal transplantation</measure>
    <time_frame>1 year</time_frame>
    <description>Immunological (lymphocyte activation and inflammatory parameters) and virologic status (kinetics of viral replication: HIV RNA in blood, total HIV DNA in PBMC) monitoring after renal transplantation. These parameters will be compared with pre-transplant status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the switch by raltegravir at the time of renal transplantation</measure>
    <time_frame>1 year</time_frame>
    <description>Assessment of ARV medications change and introduction of raltegravir at the time of renal transplantation in terms of reduction of pharmacokinetic interaction between antiretroviral regimen including raltegravir and immunosupressive treatments. In addition, virological efficacy of antiretroviral treatment including Raltegravir will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral load control after switch by antiretroviral treatment including raltegravir after renal transplantation</measure>
    <time_frame>1 year</time_frame>
    <description>The aim of this study is to evaluate at the time of renal transplantation the virologic efficiency after the switch by an antiretroviral regimen including Raltegravir in terms of viral load control an virological failure as Raltegravir is known for its low genetic barrier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival and waiting period of HIV patients registered on French biomedicine agency for renal transplantation</measure>
    <time_frame>1 year</time_frame>
    <description>Assessment of HIV patients' waiting period until renal transplantation and survival of patients registered on French biomedicine agency waiting-list compared to Non-HIV population (data provided by French Biomedicine Agency )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of Area under plasma concentration (AUC) variability of immunosuppressive drugs after introduction of antiretroviral regimen containing Raltegravir</measure>
    <time_frame>1 year</time_frame>
    <description>Area under plasma concentration (AUC) of Raltegravir and immunosuppressive drugs (Tacrolimus and Mycophenolate Mophetyl) will be measured as well as residual concentration of Tacrolimus. This study is performed in order to verify immunosupressive treatments dosage adaptation.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>HIV-1 Infection</condition>
  <condition>Chronic Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>Raltegravir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Raltegravir associated to an antiretroviral regimen without ritonavir boosted antiprotease</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir</intervention_name>
    <description>Introduction of Raltegravir 2 days after renal transplantation within an antiretroviral regimen without ritonavir boosted antiprotease</description>
    <arm_group_label>Raltegravir</arm_group_label>
    <other_name>Isentress</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Registration on the French national renal transplantation waiting list (Biomedicines
             Agency) for a living or cadaveric donor organ

          -  HIV-1-infected patients treated by a three-drug ARV regimen

          -  Immuno-virologic criteria at renal transplantation: undetectable viral load (&lt;50
             copies/mL) and CD4 &gt;200/mm3 for at least three months on stable ARV

          -  Age &gt;18 years and &lt;70 years

          -  Effective contraception for women

          -  Written informed consent

          -  Patient with social security coverage

        Exclusion Criteria:

          -  Permanent:

               -  Hepatic cirrhosis

               -  Serious psychiatric illness history

               -  EBV or HHV8 lymphoproliferation (lymphoma, systemic Kaposi's sarcoma or
                  multifocal Castleman's disease)

               -  History of PML

               -  HTLV-1 seropositivity

               -  Severe pulmonary or cardiovascular disease with poor short-term vital prognosis

               -  Patient with AgHBs+

               -  History of cryptosporidiosis

               -  History of fungal infection with multi resistant fungi not likely to respond to
                  oral antifungal therapy

               -  Impossibility or refusal of Raltegravir switch, decision made by doctor or
                  patient

          -  Temporary:

               -  Recent malignancy (between 2 and 5 years according to type)

               -  HPV-related cervical or anal disease: carcinoma in situ, AIN III, CIN III in
                  remission for less than three years

               -  Active infection

               -  HCV infection (PCR-positive)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe GRIMBERT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Henri-Mondor</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dominique COSTAGLIOLA, PHD</last_name>
    <role>Study Director</role>
    <affiliation>INSERM U943</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Pellegrin, Service de Nephrologie, Transplantation Rénale, Dialyse</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU De Caen, Service de Néphrologie Hémodialyse</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor, Service de Néphrologie Transplantation</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Kremlin Bicêtre, Service de Néphrologie</name>
      <address>
        <city>Kremlin Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Lille, Service de néphrologie</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes, Service de Néphrologie et Immunologie Clinique</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pasteur, Service de Néphrologie - Transplantation</name>
      <address>
        <city>Nice</city>
        <zip>06002</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Louis, Service de Néphrologie</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker, Service de Néphrologie adulte</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital TENON, Urgences Néphrologiques et Transplantation Rénale</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital civil, Service de Néphrologie et Transplantation</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Foch, Service de Néphrologie Transplantation</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Rangueil, Service de Néphrologie, HTA, Dialyse, Transplantation</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bretonneau, Service de Néphrologie</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.anrs.fr</url>
    <description>French National Agency for Research on AIDS and viral Hepatitis</description>
  </link>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2011</study_first_submitted>
  <study_first_submitted_qc>October 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2011</study_first_posted>
  <last_update_submitted>July 11, 2016</last_update_submitted>
  <last_update_submitted_qc>July 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Raltegravir</keyword>
  <keyword>Renal transplantation</keyword>
  <keyword>HIV-1</keyword>
  <keyword>Acute renal graft rejection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

